Atrial fibrillation: Maintenance of sinus rhythm versus rate control

American Journal of Cardiology

Volumn 77, Issue 3, 1996, Pages 24A-37A

  Sopher, S Mark ^a   Camm, A John ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIGOXIN; DILTIAZEM; DISOPYRAMIDE; DOFETILIDE; FLECAINIDE; IBUTILIDE FUMARATE; PINDOLOL; PROCAINAMIDE; PROPAFENONE; QUINIDINE; SOTALOL; VERAPAMIL; WARFARIN; XAMOTEROL;

ATRIOVENTRICULAR BLOCK; BRADYCARDIA; CARDIOVERSION; CATHETER ABLATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG CONTRAINDICATION; DRUG INDICATION; HEART ATRIUM FIBRILLATION; HEART ATRIUM PACING; HEART FAILURE; HEART SUPRAVENTRICULAR ARRHYTHMIA; HEART VENTRICLE FIBRILLATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MEDICAL DECISION MAKING; META ANALYSIS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; SINUS RHYTHM; STROKE; SUDDEN DEATH; THROMBOEMBOLISM;

EID: 0030029270     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(97)89115-1     Document Type: Conference Paper

References (128)

1. Khalsa A, Olsson B, Henriksson B. Effect of oral verapamil on ventricular irregularity in long-standing atrial fibrillation. Acta Med Scand 1979;205:39-47.
2. Peters KG, Kienzle MG. Severe cardiomyopathy due to chronic rapidly conducted atrial fibrillation: complete recovery after restoration of sinus rhythm. Am J Med 1988;85:242-244.
3. Grogan M, Smith HC, Gersh BJ, Wood DL. Left ventricular dysfunction due to atrial fibrillation in patients initially believed to have idiopathic dilated cardiomyopathy. Am J Cardiol 1992;69:1570-1573.
4. Gosselink ATM, Crijns HJ, Van Den Berg MP, Van den Broek SAJ, Hillege H, Landsman ML, Lie KI. Functional capacity before and after cardioversion of atrial fibrillation: a controlled study. Br Heart J 1994;72:161-166.
5. Brand FN, Abbott RD, Kannel WB, Wolf PA. Characteristics and prognosis of lone atrial fibrillation. Thirty year follow up in the Framingham study. JAMA 1985;254:3449-3453.
6. Kopecky SL, Gersh BJ, McGoon MD, Whisnant JP, Holmes DR, Jr., Ilstrup DM, Frye RL. The natural history of lone atrial fibrillation. A population base study over three decades. N Engl J Med 1987;317:669-674.
7. Montoya PT, Brugada P, Smeets J, Talajic M, Bella PD, Lezaun R, Dool A vd, Wellen WI, Bayes de Luna A, Oter R, Breithardt G, Borggrefe M, Klein H, Kuck KH, Kunze K, Coumel P, Leclercq IF, Chouty F, Frank R, Fontaine G. Ventricular fibrillation in the Wolff-Parkinson-White syndrome. Eur Heart J 1991;12:144-150.
8. Stafford WJ, Trohman RG, Bilsker M, Zaman L, Castellanos A, Myerburg RJ. Cardiac arrest in an adolescent with atrial fibrillation and hypertrophic cardiomyopathy. J Am Coll Cardiol 1986;7:701-704.
9. Zipes DP. Specific arrhythmias: diagnosis and treatment. In: Braunwald E, ed. Heart disease. A Textbook of Cardiovascular Medicine. Philadelphia: WB Saunders, 1992.
10. Storstein L. Role of digitalis in ventricular rate control in atrial fibrillation. In: Kulbertus HE, Olsson SB, Schlepper M, eds. Atrial Fibrillation. Mölndal, Sweden: A.B. Hassle, 1984;1-288.
11. Camm AJ. The recognition and management of tachyarrhythmias. In: Julian DG, Camm AJ, Fox KM, Hall RJC, Poole-Wilson PA, eds. Diseases of the Heart. London: Bailliére Tindall, 1989;1-516.
12. Bigger JT. Heart Disease. Philadelphia: W.B. Saunders, 1980;1-731.
13. Rawles JM. What is meant by a "controlled" ventricular rate in atrial fibrillation? Br Heart J 1990;63:157-161.
14. Toivonen LK, Kadish AH, Kou W, Morady F. Determinants of the ventricular rate during atrial fibrillation. J Am Coll Cardiol 1990;16:1194-1200.
15. Smith TW. Digitalis. Mechanisms of action and clinical use. N Engl J Med 1988;318:358-365.
16. Gillis RA, Quest JA. The role of the nervous system in the cardiovascular effects of digitalis. Pharmacol Rev 1979;31:19-97.
17. Beasley R, Smith DA, McHaffie DJ. Exercise heart rates at different serum digoxin concentrations in patients with atrial fibrillation. Br Med J 1985;290:9-11.
18. Klein HO, Kaplinsky E. Digitalis and verapamil in atrial fibrillation and flutter. Is verapamil now the preferred agent? Drugs 1986;31:185-197.
19. Falk RH, Leavitt JI. Digoxin for atrial fibrillation: a drug whose time has gone? Ann Intern Med 1991;114:573-575.
20. Braunwald E. Effects of digitalis on the normal and the failing heart. (Abstr.) J Am Coll Cardiol 1985;5:51A-59A.
21. Channer KS, Papouchado M, James MA, Pitcher DW, Rees JR. Towards improved control of atrial fibrillation. Eur Heart J 1987;8:141-147.
22. Lewis RV, Irvine N, McDevitt DG. Relationships between heart rate, exercise tolerance and cardiac output in atrial fibrillation: the effects of treatment with digoxin, verapamil and diltiazem. Eur Heart J 1988;9:777-781.
23. Atwood JE, Myers J, Sullivan M, Forbes S, Friis R, Pewen W, Callaham P, Hall P, Froelicher V. Maximal exercise testing and gas exchange in patients with chronic atrial fibrillation. J Am Coll Cardiol 1988;11:508-513.
24. Galun E, Flugelman MY, Glickson M, Eliakim M. Failure of long-term digitalization to prevent rapid ventricular response in patients with paroxysmal atrial fibrillation. Chest 1991;99:1038-1040.
25. Coumel P. Role of the autonomie nervous system in paroxysmal atrial fibrillation. In: Touboul P, Waldo AL, eds. Atrial Arrhythmias. Current Concepts and Management. St Louis: Mosby-Year Book, 1990;248-261.
26. Rawles JM, Metcalfe MJ, Jennings K. Time of occurrence, duration, and ventricular rate of paroxysmal atrial fibrillation: the effect of digoxin. Br Heart J 1990;63:225-227.
27. Falk RH, Knowlton AA, Bernard SA, Gotlieb NE, Battinelli NJ. Digoxin for converting recent-onset atrial fibrillation to sinus rhythm. A randomized, double-blinded trial. Ann Intern Med 1987;106:503-506.
28. Roth A, Kaluski E, Fenner S, Heller K, Laniado S. Clonidine for patients with rapid atrial fibrillation. Ann Intern Med 1992;116:388-390.
29. Ahuja RC, Sinha N, Saran RK, Jain AK, Hasan M. Digoxin or verapamil or metoprolol for heart rate control in patients with mitral stenosis-a randomised cross-over study. Int J Cardiol 1989;25:325-331.
30. Matsuda M, Matsuda Y, Yamagishi T, Takahashi T, Haraguchi M, Tada T, Kusukawa R. Effects of digoxin, propranolol, and verapamil on exercise in patients with chronic isolated atrial fibrillation. Cardiovasc Res 1991;25:453-457.
31. Dahlstrom CG, Edvardsson N, Nasheng C, Olsson SB. Effects of diltiazem, propranolol, and their combination in the control of atrial fibrillation. Clin Cardiol 1992;15:280-284.
32. Zoble RG, Brewington J, Olukotun AY, Gore R. Comparative effects of nadolol-digoxin combination therapy and digoxin monotherapy for chronic atrial fibrillation. Am J Cardiol 1987;60(suppl):39D-45D.
33. DiBianco R, Morganroth J, Freitag JA, Ronan JAJ, Lindgren KM, Donohue DJ, Larca LJ, Chadda KD, Olukotun AY. Effects of nadolol on the spontaneous and exercise-provoked heart rate of patients with chronic atrial fibrillation receiving stable dosages of digoxin. Am Heart J 1984;108:1121-1127.
34. Lewis RV, McMurray J, McDevitt DG. Effects of atenolol, verapamil, and xamoterol on heart rate and exercise tolerance in digitalised patients with chronic atrial fibrillation. J Cardiovasc Pharmacol 1989;13:1-6.
35. James MA, Channer KS, Papouchado M, Rees JR. Improved control of atrial fibrillation with combined pindolol and digoxin therapy. Eur Heart J 1989;10:83-90.
36. Lundstrom T, Ryden L. Ventricular rate control and exercise performance in chronic atrial fibrillation: effects of diltiazem and verapamil. J Am Coll Cardiol 1990;16:86-90.
37. Lang RM, Klein HO, Di Segni E, Gefen J, Sareli P, Libhaber C, David D, Weiss E, Guerrero J, Kaplinsky E. Verapamil improves exercise capacity in chronic atrial fibrillation: double-blind crossover study. Am Heart J 1983;105: 820-825.
38. Scheinman MM, Morady F, Hess DS, Gonzalez R. Catheter induced ablation of the atrioventricular junction to control refractory supraventricular arrhythmias. JAMA 1982;248:851-855.
39. Gallagher JJ, Svensen RH, Kasell JH, German LD, Bardy GH, Broughton A, Critelli G. Catheter technique for closed chest ablation of the atrioventricular conduction system. A therapeutic alternative for the treatment of refractory supraventricular tachycardia. N Engl J Med 1982;306:194-200.
40. Sharma AD, Klein GJ, Guiraudon GM, Milstein S. Atrial fibrillation in patients with Wolff-Parkinson-White syndrome: incidence after surgical ablation of the accessory pathway. Circulation 1985;72:161-169.
41. Haissaguerre M, Fischer B, Labbe T, Lemetayer P, Montserrat P, d'Ivernois C, Dartigues JF, Warin JF. Frequency of recurrent atrial fibrillation after catheter ablation of overt accessory pathways. Am J Cardiol 1992;69:493-497.
42. Wathen M, Natale A, Wolfe K, Yee R, Klein G. Initiation of atrial fibrillation in the Wolff-Parkinson-White syndrome: the importance of the accessory pathway. Am Heart J 1993;125:753-759.
43. Twidale N, Sutton K, Bartlett L, Dooley A, Winstanley S, Heddle W, Hassam R, Koutsounis H. Effects on cardiac performance of atrioventricular node catheter ablation using radiofrequency current for drug-refractory atrial arrhythmias. PACE 1993;16:1275-1284.
44. Kay GN, Bubien RS, Epstein AE, Plumb VJ. Effect of catheter ablation of the atrioventricular junction on quality of life and exercise tolerance in paroxysmal atrial fibrillation. Am J Cardiol 1988;62:741-744.
45. Williamson BD, Man KC, Daoud E, Niebauer M, Strickberger SA, Morady F. Radiofrequency catheter modification of atrioventricular conduction to control the ventricular rate during atrial fibrillation. N Engl J Med 1994;331:910-917.
46. Feld GK, Fleck P, Fujimura O, Prothro DL, Bahnson TD, Ibarra M. Control of rapid ventricular response by radiofrequency catheter modification of the atrioventricular node in patients with medically refractory atrial fibrillation. Circulation 1994;90:2299-2307.
47. Della Bella P, Carbucicchio C, Tondo C, Riva S. Modulation of atrioventricular conduction by ablation of the "slow" atrioventricular node pathway in patients with drug-refractory atrial fibrillation or flutter. J Am Coll Cardiol 1995;25:39-46.
48. Duckeck W, Engelstein ED, Kuck KH. Radiofrequency current therapy in atrial tachyarrhythmias: modulation versus ablation of atrioventricular nodal conduction. PACE 1993;16:629-636.
49. Guiraudon GM, Campbell CS, Jones DL, McLellan JL, MacDonald JL. Combined sinoatrial node atrioventricular node isolation: a surgical alternative to His bundle ablation in patients with atrial fibrillation. (Abstr.) Circulation 1985;72:III-220.
50. Leitch JW, Klein GJ, Yee R, Guiraudon GM. Sinus node-atrioventricular node isolation: long-term results with the "corridor" operation for atrial fibrillation. J Am Coll Cardiol 1991;17:970-975.
51. Defauw JJ, Guiraudon GM, van Hemel NM, Vermeulen FE, Kingma JH, de Bakker JM. Surgical therapy of paroxysmal atrial fibrillation with the "corridor" operation. Ann Thorac Surg 1992;53:564-570.
52. Langendorf R, Pick A, Katz LN. Ventricular response in atrial fibrillation. Role of concealed conduction in the AV junction. Circulation 1965;32:69-75.
53. Wittkampf FH, de Jongste MJ, Lie HI, Meijler FL. Effect of right ventricular pacing on ventricular rhythm during atrial fibrillation. J Am Coll Cardiol 1988;11:539-545.
54. Lau C-P, Leung W-H, Wong C-K, Tai Y-T, Cheng C-H. A new pacing method for rapid regularization and rate control in atrial fibrillation. Am J Cardiol 1990;65:1198-1203.
55. Borgeat A, Goy JJ, Maendly R, Kaufmann U, Grbic M, Sigwart U. Flecainide versus quinidine for conversion of atrial fibrillation to sinus rhythm. Am J Cardiol 1986;58:496-498.
56. Hellestrand KJ. Intravenous flecainide acetate for supraventricular tachycardias. Am J Cardiol 1988;62(suppl):16D-22D.
57. Goy JJ, Maendly R, Grbic M, Finci L, Sigwart U. Cardioversion with flecainide in patients with atrial fibrillation of recent onset. Eur J Clin Pharmacol 1985;27:737-738.
58. Crijns HJ, Van Wijk LM, Van Gilst WH, Kingma JH, Van Gelder IC, Lie KI. Acute conversion of atrial fibrillation to sinus rhythm: clinical efficacy of flecainide acetate. Comparison of two regimens. Eur Heart J 1988;9:634-638.
59. Suttorp MJ, Kingma JH, Lie AH, Mast EG. Intravenous flecainide versus verapamil for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. Am J Cardiol 1989;63:693-696.
60. Suttorp MJ, Kingma JH, Jessurun ER, Lie AH, van Hemel NM, Lie KI. The value of class IC antiarrhythmic drugs for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. J Am Coll Cardiol 1990;16: 1722-1727.
61. Bianconi L, Boccadamo R, Pappalardo A, Gentili C, Pistolese M. Effectiveness of intravenous propafenone for conversion of atrial fibrillation and flutter of recent onset. Am J Cardiol 1989;64:335-338.
62. Faniel R, Schoenfeld P. Efficacy of i.v. amiodarone in converting rapid atrial fibrillation and flutter to sinus rhythm in intensive care patients. Eur Heart J 1983;4:180-185.
63. Anastasiou Nana MI, Levis GM, Moulopoulos SD. Amiodarone-application and clinical pharmacology in atrial fibrillation and other arrhythmias. Int J Clin Pharmacol Ther Toxicol 1984;22:229-235.
64. Strasberg B. Intravenous amiodarone for conversion of atrial fibrillation to sinus rhythm. Am J Cardiol 1991;67:325.
65. Mostow ND, Vrobel TR, Noon D, Rakita L. Rapid control of refractory atrial tachyarrhythmias with high-dose oral amiodarone. Am Heart J 1990;120: 1356-1363.
66. Lown B, Amarasingham R, Neuman J. New method for terminating cardiac arrhythmias - use of synchronized capacitor discharge. JAMA 1962;182: 548-555.
67. Van Gelder IC, Crijns HJ, Blanksma PK, Landsman ML, Posma JL, Van Den Berg MP, Meijler FL, Lie KI. Time course of hemodynamic changes and improvement of exercise tolerance after cardioversion of chronic atrial fibrillation unassociated with cardiac valve disease. Am J Cardiol 1993;72:560-566.
68. Kubac G, Malowany L. Functional capacity of patients with atrial fibrillation and controlled heart rate before and after cardioversion. Can J Cardiol 1992;8:941-946.
69. Rossi M, Lown B. The use of quinidine in cardioversion. Am J Cardiol 1967;19:234-238.
70. Levy S, Lauribe P, Dolla E, Kou W, Kadish A, Calkins H, Pagannelli F, Moyal C, Bremondy M, Schork A. A randomized comparison of external and internal cardioversion of chronic atrial fibrillation. Circulation 1992;86: 1415-1420.
71. Van Gelder IC, Crijns HJ, Van Gilst WH, Verwer R, Lie KI. Prediction of uneventful cardioversion and maintenance of sinus rhythm from direct-current electrical cardioversion of chronic atrial fibrillation and flutter. Am J Cardiol 1991;68:41-46.
72. Lown B. Electrical reversion of cardiac arrhythmias. Br Heart J 1967;29: 469-489.
73. Metcalfe MJ, Smith F, Jennings K, Patterson N. Does cardioversion of atrial fibrillation result in myocardial damage? Br Med J 1988;290:1364.
74. Manning WJ, Leeman DE, Gotch PJ, Come PC. Pulsed Doppler evaluation of atrial mechanical function after electrical cardioversion of atrial fibrillation. J Am Coll Cardiol 1989;59:572-577.
75. Bardy GH, Ivey TD, Coltorti F, Stewart RB, Johnson G, Greene HL. Developments, complications and limitations of catheter-mediated electrical ablation of posterior accessory atrioventricular pathways. Am J Cardiol 1988;61: 309-316.
76. Alt E, Schmitt C, Ammer R, Coenen M, Fotuhi P, Karch M, Blasini R. Initial experience with intracardiac atrial defibrillation in patients with chronic atrial fibrillation. PACE 1994;17:1067-1078.
77. Coplen SE, Antman EM, Berlin JA, Hewitt P, Chalmers TC. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials. Circulation 1990;82: 1106-1116.
78. Falk RH, Podrid PJ. Electrical cardioversion of atrial fibrillation. In Falk RH, Podrid PJ, eds. Atrial Fibrillation. Mechanisms and Management. New York: Raven Press, 1992;181-195.
79. Lundstrom T, Ryden L. Chronic atrial fibrillation. Long-term results of direct current conversion. Acta Med Scand 1988;223:53-59.
80. Boissel JP, Wolf E, Gillet J, Soubrane A, Cavallaro A, Mazoyer G, Delahaye JP. Controlled trial of a long-acting quinidine for maintenance of sinus rhythm after conversion of sustained atrial fibrillation. Eur Heart J 1981;2: 49-55.
81. Sodermark T, Jonsson B, Olsson A, Oro L, Wallin H, Edhag O, Sjogren A, Danielsson M, Rosenhamer G. Effect of quinidine on maintaining sinus rhythm after conversion of atrial fibrillation or flutter. A multicentre study from Stockholm. Br Heart J 1975;37:486-492.
82. Byrne Quinn E, Wing AJ. Maintenance of sinus rhythm after DC reversion of atrial fibrilllation. A double-blind controlled trial of long-acting quinidine bisulphate. Br Heart J 1970;32:370-376.
83. Hillestad L, Bjerkelund C, Dale J, Maltau J, Storstein O. Quinidine in maintenance of sinus rhythm after electroconversion of chronic atrial fibrillation. A controlled clinical study. Br Heart J 1971;33:518-521.
84. Hartel G, Louhija A, Konttinen A, Halonen PI. Value of quinidine in maintenance of sinus rhythm after electric conversion of atrial fibrillation. Br Heart J 1970;32:57-60.
85. Karlson BW, Torstensson I, Abjorn C, Jansson SO, Peterson LE. Disopyramide in the maintenance of sinus rhythm after electroconversion of atrial fibrillation. A placebo-controlled one-year follow-up study. Eur Heart J 1988;9: 284-290.
86. Hartel G, Louhija A, Konttinen A. Disopyramide in the prevention of recurrence of atrial fibrillation after electroconversion. Clin Pharmacol Ther 1974;15:551-555.
87. Szekely P, Sideris DA, Batson GA. Maintenance of sinus rhythm after atrial defibrillation. Br Heart J 1970;32:741-746.
88. Juul Moller S, Edvardsson N, Rehnqvist Ahlberg N. Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation. Circulation 1990;82:1932-1939.
89. Rasmussen K, Anderson A, Abrahamsen AM, Overskeid K, Bathen J. Flecainide versus disopyramide in maintaining sinus rhythm following conversion of chronic atrial fibrillation. (Abstr.) Eur Heart J 1989;9:52.
90. Reimold SC, Cantillon CO, Friedman PL, Antman EM. Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. Am J Cardiol 1993;71:558-563.
91. Crijns HJ, Van Gelder IC, Van Gilst WH, Hillege H, Gosselink ATM, Lie KI. Serial antiarrhythmic drug treatment to maintain sinus rhythm after electrical cardioversion for chronic atrial fibrillation or atrial flutter. Am J Cardiol 1991;68:335-341.
92. Gosselink ATM, Crijns HJ, Van Gelder IC, Hillige H, Wiesfeld AC, Lie KI. Low-dose amiodarone for maintenance of sinus rhythm after cardioversion of atrial fibrillation or flutter. JAMA 1992;267:3289-3293.
93. Brodsky MA, Allen BJ, Walker CJ, Casey TP, Luckett CR, Henry WL. Amiodarone for maintenance of sinus rhythm after conversion of atrial fibrillation in the setting of a dilated left atrium. Am J Cardiol 1987;60:572-575.
94. Falk RH. Proarrhythmia in patients treated for atrial fibrillation or flutter. Ann Intern Med 1992;117:141-150.
95. Pritchett ELC, Wilkinson WE. Mortality in patients treated with flecainide and encainide for supraventricular arrhythmias. Am J Cardiol 1991;67:976-980.
96. Cowan JC. Antiarrhythmic drugs in the management of atrial fibrillation. Br Heart J 1993;70:304-306.
97. Selzer A, Wray HW. Quinidine syncope: paroxysmal ventricular fibrillation occurring during treatment of chronic atrial arrhythmias. Circulation 1964;30: 17-26.
98. Radford MD, Evans DW. Long-term results of DC reversion of atrial fibrillation. Br Heart J 1968;30:91-96.
99. Ruskin JN. The Cardiac Arrhythmia Suppression Trial (CAST). N Engl J Med 1989:321:386-388.
100. Flaker GC, Blackshear JL, McBride R, Kronmal RA, Halperin JL, Hart RG. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. J Am Coll Cardiol 1992;20:527-532.
101. Falk RH. Flecainide-induced ventricular tachycardia and fibrillation in patients treated for atrial fibrillation. Ann Intern Med 1989:111:107-111.
102. Marcus FI. The hazards of using type 1C antiarrhythmic drugs for the treatment of paroxysmal atrial fibrillation. Am J Cardiol 1990;66:366-367.
103. Page RL, Wilkinson WE, Clair WK, McCarthy EA, Pritchett ELC. Asymptomatic arrhythmias in patients with symptomatic paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia. Circulation 1994;89: 224-227.
104. Anderson JL, Gilbert EM, Alpert BL, Henthom RW, Waldo AL, Bhandari AK, Hawkinson RW, Pritchett ELC. Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy. A multicenter, double-blind, crossover study of flecainide and placebo with transtelephonic monitoring. Flecainide Supraventricular Tachycardia Study Group. Circulation 1989;80:1557-1570.
105. Connolly SJ, Hoffert DL. Usefulness of propafenone for recurrent paroxysmal atrial fibrillation. Am J Cardiol 1989;63:817-819.
106. Pritchett ELC, McCarthy EA, Wilkinson WE. Propafenone treatment of symptomatic paroxysmal supraventricular arrhythmias. A randomized, placebo-controlled, crossover trial in patients tolerating oral therapy. Ann Intern Med 1991;114:539-544.
107. Cobbe SM. A randomized, placebo-controlled trial of propafenone in the prophylaxis of paroxysmal supraventricular tachyarrythmias. (Abstr.) J Am Coll Cardiol 1994;23:251A.
108. Lau CP, Leung WH, Wong CK. A randomized double-blind crossover study comparing the efficacy and tolerability of flecainide and quinidine in the control of patients with symptomatic paroxysmal atrial fibrillation. Am Heart J 1992;124:645-650.
109. Antman EM, Beamer AD, Cantillon C, McGowan N, Friedman PL. Therapy of refractory symptomatic atrial fibrillation and atrial flutter: a staged care approach with new antiarrhythmic drugs. J Am Coll Cardiol 1990;15: 698-707.
110. Murgatroyd FD, Xie B, Gibson SM, Ward DE, Malik M, Camm AJ. The effects of digoxin in patients with paroxysmal atrial fibrillation: analysis of Holter data from the CRAFT-1 trial. (Abstr.) J Am Coll Cardiol 1993;21:203A.
111. Coumel P, Escoubet B, Attuel P. Beta-blocking therapy in atrial and ventricular tachyarrhythmias: experience with nadolol. Am Heart J 1984;108: 1098-1108.
112. Murgatroyd FD, O'Farrell DM, Foran JP, Kelly SJ, Ward DE, Camm AJ. A multi-centre double blind crossover comparison of disopyramide, atenolol and placebo for symptomatic paroxysmal atrial fibrillation. J Am Coll Cardiol 1995;25:1347-1353.
113. Horowitz LN, Spielman SR, Greenspan AM, Mintz GS, Morganroth J, Brown R, Brady PM, Kay HR. Use of amiodarone in the treatment of persistent and paroxysmal atrial fibrillation resistant to quinidine therapy. J Am Coll Cardiol 1985;6:1402-1407.
114. Cox JL. The surgical treatment of atrial fibrillation. IV. Surgical technique. J Thorac Cardiovasc Surg 1991;101:584-592.
115. Cox JL, Schuessler RB, Boineau JP. The surgical treatment of atrial fibrillation. I. Summary of the current concepts of the mechanisms of atrial flutter and atrial fibrillation. J Thorac Cardiovasc Surg 1991;101:402-405.
116. Cox JL, Canavan TE, Schuessler RB, Cain ME, Lindsay BD, Stone C, Smith PK, Corr PB, Boineau JP. The surgical treatment of atrial fibrillation. II. Intraoperative electrophysiologic mapping and description of the electrophysiologic basis of atrial flutter and atrial fibrillation. J Thorac Cardiovasc Surg 1991;101:406-426.
117. Cox JL, Schuessler RB, D'Agostino HJJ, Stone CM, Chang BC, Cain ME, Corr PB, Boineau JP. The surgical treatment of atrial fibrillation. III. Development of a definitive surgical procedure. J Thorac Cardiovasc Surg 1991;101:569-583.
118. McCarthy PM, Castle LW, Maloney JD, Trohman RG, Simmons TW, White RD, Klein AL, Cosgrove DM. Initial experience with the maze procedure for atrial fibrillation. J Thorac Cardiovasc Surg 1993;105:1077-1087.
119. Elvan A, Pride HP, Eble JN, Zipes DP. Radiofrequency catheter ablation of the atria reduces inducibility and duration of atrial fibrillation in dogs. Circulation 1995;91:2235-2244.
120. Swartz JF, Pellersels G, Silvers J, Patten L, Cervantes D. A catheter-based curative approach to atrial fibrillation in humans. (Abstr.) Circulation 1994;90:I-335.
121. Haissaguerre M, Gencel L, Fischer B, Le Métayer P, Poquet F, Marcus FI, Clémenty J. Successful catheter ablation of atrial fibrillation. J Cardiovasc Electrophysiol 1994;5:1045-1052.
122. Andersen HR, Thuesen L, Bagger JP, Vesterlund T, Thomsen PEB. Prospective randomized trial of atrial versus ventricular pacing in sick-sinus syndrome. Lancet 1994;344:1523-1528.
123. Attuel P, Pellerin D, Mugica J, Coumel P. DDD pacing: an effective treatment modality for recurrent atrial arrhythmias. PACE 1988;11:1647-1654.
124. Murgatroyd FD, Slade AKB, Jones S, Nitzsche R, Rowland E, Camm AJ, Limousin M, Ritter P, Chorus Multicentre Study Group: A new pacing algorithm for the suppression of atrial fibrillation. (Abstr.) Br Heart J 1994; 71:P14.
125. Daubert C, Mabo P, Berder V, Gras D, Leclercq C. Atrial tachyarrhyhtmias associated with high degree interatrial conduction block: prevention by permanent atrial resynchronization. Eur J C P E 1994;4:35-444.
126. Ayers GM, Griffin JC, Ilina MB, Wagner DO, Sirokman WA, Bocek JM, White HG, Alferness CA. An implantable atrial defibrillator: initial experience with a novel device. (Abstr.) PACE 1994;17:769.
127. Murgatroyd FD, Johnson EE, Cooper RA, Lau CP, Alt E, Kappenberger LJ, Smith JM, Camm AJ, Wharton JM. Safety of low energy transvenous atrial defibrillation - world experience. Circulation 1994;90:14(Abstract).
128. Murgatroyd FD, Slade AKB, O'Farrell DM, Rowland E, Ward DE, Camm AJ. Transvenous low-energy cardioversion of short-duration atrial fibrillation in humans. (Abstr.) J Am Coll Cardiol 1994;23:126A.